================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
Monday, March 22, 2004
TRANSGENOMIC, INC.
(Exact name of registrant as specified in its charter)
Delaware 000-30975
(State of Formation) (Commission File Number)
911789357
(IRS Employer Identification Number)
12325 Emmet Street
Omaha, NE 68164
(Address of principal executive offices) (Zip Code)
(402) 452-5400
(Registrants' telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
================================================================================
Item 5. Other Events and Regulation FD Disclosure.
On Monday, March 22, 2004, the Company issued a press release announcing
that it has signed a contract with North Carolina-based Regado Biosciences to
manufacture two components of an antidote-controlled, regulatable anticoagulant
therapy, and provide a range of related services.
Item 7. Financial Statements and Exhibits.
(c) Exhibits
99.1 Press Release, dated Monday, March 22, 2004, announcing that the Company
has signed a contract with North Carolina-based Regado Biosciences to
manufacture two components of an antidote-controlled, regulatable
anticoagulant therapy, and provide a range of related services.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
TRANSGENOMIC, INC.
By /s/ Michael J. Draper
------------------------------------------
Michael J. Draper, Chief Financial Officer
Monday, March 22, 2004
3